Home > Insider Trading > Filing (0001140361-12-047147)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377232	Phd J Michael Williams	One Idexx Drive Westbrook ME 04092	Executive Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-11-12	12,449	$34.37	19,914	No	4	M	Direct
Common Stock	Acquisiton	2012-11-12	2,500	$28.66	22,414	No	4	M	Direct
Common Stock	Acquisiton	2012-11-12	1,294	$28.66	23,708	No	4	M	Direct
Common Stock	Disposition	2012-11-12	12,449	$89.13	11,259	No	4	S	Direct
Common Stock	Disposition	2012-11-12	1,294	$89.16	9,965	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2012-11-12	12,449	$0.00	12,449	$34.37
Common Stock	Incentive Stock Option	Disposition	2012-11-12	2,500	$0.00	2,500	$28.66
Common Stock	Incentive Stock Option	Disposition	2012-11-12	1,294	$0.00	1,294	$28.66

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,390	2016-02-13	No	4	M	Direct
1,294	2015-02-02	No	4	M	Direct
0	2015-02-02	No	4	M	Direct

Footnotes

The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $89.00 to $89.59, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $89.15 to $89.16, inclusive.
Grant of options to buy shares of common stock becomes exercisable as to 4,149 shares on 02/14/2010, 4,150 shares on 02/14/2011, 4,150 shares on 02/14/2012, 4,149 shares on 02/14/2013, and the remaining 1,241 shares on 02/14/2014.
Grant of options to buy shares of common stock becomes exercisable as to 1,074 shares on 02/03/2009 and the remaining 2,720 shares on 02/03/2010.